<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T14:22:15Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10230/21136" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10230/21136</identifier><datestamp>2025-12-13T20:52:36Z</datestamp><setSpec>com_2072_6</setSpec><setSpec>col_2072_452954</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Neutralizing antibodies in Multiple Sclerosis a model-based analysis of Interferon beta signaling pathway in macrophages</dc:title>
   <dc:creator>Domingo Espinós, Júlia, 1991-</dc:creator>
   <dc:subject>Esclerosi múltiple</dc:subject>
   <dc:subject>Treball de fi de grau -- Curs 2012-2013</dc:subject>
   <dcterms:abstract>Treball de fi de grau en Biologia Humana</dcterms:abstract>
   <dcterms:abstract>Supervisors: Jordi Garcia Ojalvo i/nElena Abad</dcterms:abstract>
   <dcterms:abstract>Multiple Sclerosis is the most common non-traumatic cause of neurological/ndisability in young people. There is no cure yet, and until recently, few long-term/ntherapies existed. Interferon beta (IFNβ) was the first treatment, and remains the most/ncommonly prescribed. One of the most significant problems of IFNβ therapy is the/nproduction of drug specific antibodies. Up to 45% of patients develop neutralizing/nantibodies (NAbs) to IFNβ products. The neutralizing antibody binds to the biological/nagent preventing its interaction with its receptor, inhibiting the biological action of the/nprotein, which abrogates the clinical efficacy of IFNβ treatment. Interferon-beta/nmediates its response by binding to its high affinity cell surface receptor and initiating/nthe JAK/STAT signalling cascade. In this project we have analyzed the IFNβ signaling/npathway in macrophages when neutralizing antibodies are present. The response to/nthis pathway after IFNβ stimulation shows a transient oscillatory rhythm of STAT1/nphosphorylation, which varies as NAbs concentration increases. To improve our/nunderstanding of that behavior, we extended an existing mathematical model based on/nnonlinear ordinary differential equations of JAK/STAT pathway by including IFN-NAb/nassociation and IFN-activation receptor. Combining our theoretical model with/nexperimental data we could study the role of neutralizing antibodies on the molecular/nresponse and determine its lifetime after cytokine stimulation.</dcterms:abstract>
   <dcterms:issued>2013-09-30T15:15:22Z</dcterms:issued>
   <dcterms:issued>2013-09-30T15:15:22Z</dcterms:issued>
   <dcterms:issued>2013-09-30</dcterms:issued>
   <dc:type>info:eu-repo/semantics/bachelorThesis</dc:type>
   <dc:rights>© Tots els drets reservats</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>